Eric M Gordon
Founder & Partner @ Skyline Ventures
Palo Alto, United States
Eric M Gordon is a startup investor at Skyline Ventures in Palo Alto. Eric has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s. He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years. In 1992, he became Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and had that role untilthe company was sold to Glaxo in 1995. In 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005). In 1998 he participated in the early stages of Sunesis Pharmaceuticals (NASDAQ: SNSS) and was Senior Vice President of Research until late 2002. He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition. Eric has authored more than 200 scientific manuscripts and U.S. patents, and portions of 3 books, including editing a comprehensive book on combinatorial chemistry. He is the senior author of two manuscripts which during 1994-1996 were the most frequently cited chemistry papers in the world. He is on the Scientific Advisory Boards of the Cystic Fibrosis Foundation and the Organization for One World Health, as well as several biotechnology companies. He serves on the Editorial Advisory Board of five scientific journals. In 1997 he was elected a Fellow of the American Association for the Advancement of Science (AAAS). He received his Ph.D. and M.S. in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University. He joined Skyline in 2002. Like John, he is a lifelong Yankee fan, but is old enough to have attended Woodstock, the Beatles concert at Shea Stadium in 1965, and the 1968 Democratic Convention in Chicago.
Last updated:
For AI agents: llms.txt
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
About Skyline Ventures
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Their areas of expertise include small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research.They allhave MD or PhD degrees, and hands-on operating experience in various start-up healthcare companies that later went public. As a result, they are known for the value they offer their companies, as board members and shareholders. They are also known for being fundamental, extremely patient investors.The days when momentum investing drove the public biotechnology markets are long gone, and they are glad that they are. The public markets demand data, not dreams. As a result, it is data that drives their decision process. In considering a new investment, they focus on whether there is adequate proof of principle to believe that the company's products will work.In therapeutics, for example, they look closely at whether the biochemistry, animal models and any human data make it more probable than average that the product will eventually prove to have an important therapeutic benefit. The size of the potential market and the quality of the management or founding team are critical in their evaluation as well.Skyline Ventures are value and return driven, more than driven by the stage of the investment. Most often they lead or co-lead a company's first or second institutional venture round, but have previously helped found companies and invested in PIPEs and leveraged buyouts.In October 2007, they completed raising Skyline V, which has $350 million in committed capital. They have approximately $800 million under management. They target investments of $15-35 million per portfolio company over the life of the company.
Skyline Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Eric M Gordon
Founder & Partner
|
|||
John Freund
Founder & Managing Director
|
|||
Stephen J. Hoffman
Managing Director
|
|||
Yasunori Kaneko
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
How do I contact Eric M Gordon?
Public channels for Eric M Gordon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
